Rationale, design, and baseline data of the insulin glargine (lantus) versus insulin detemir (levemir) treat-to-target (l2t3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 11, Issue 11, 2009, Pages 739-743

  Swinnen, Sanne G H A ^a   Snoek, Frank J ^b   Dain, Marie Paule ^c   Devries, J Hans ^a   Hoekstra, Joost B L ^a   Holleman, Frits ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CREATININE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES CONTROL; DIABETIC PATIENT; DIET RESTRICTION; DISTRESS SYNDROME; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; EMOTIONAL STABILITY; EVENING DOSAGE; EXERCISE; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF CARE; SELF REPORT; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 70449629461     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0044     Document Type: Article

References (27)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetesmellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
4. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-1349.
5. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540.
6. Nakar S, Yitzhaki G, Rosenberg R, Vinker S: Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007;21:220-226.
7. Holleman F, Gale E: Nice insulins, pity about the evidence. Diabetologia 2007;50:1783-1790.
8. Rosenstock J, Davies M, Home P, Larsen J, Koenen C, Schernthaner G: A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetologia 2008;51:408-416.
9. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P: A 26-week, randomized, parallel, treatto- target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetes Care 2006;29: 1269-1274. Erratum Diabetes Care 2007;30:1035.
10. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-3086.
11. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;CD005613.
12. EMEA: Levemir European Public Assessment Report. Revision 10, 22 July 2008. http:==www.emea.europa.eu=humandocs= Humans=EPAR=levemir=levemir.htm (accessed February 13, 2009).
13. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-1581.
14. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, Group TS: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
15. Rubin RR, Peyrot M: Quality of life and diabetes. Diabetes Metab Res Rev 1999;15:205-218.
16. Wexler D, Grant R, Wittenberg E, Bosch J, Cagliero E, Delahanty L, Blais M, Meigs J: Correlates of health-related quality of life in type 2 diabetes. Diabetologia 2006;49:1489-1497.
17. Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC: Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT study. Diabetes Res Clin Pract 2007;78: 254-258.
18. Vinik AI, Zhang Q: Adding insulin glargine versus rosiglitazone: Health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007;30:795-800.
19. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabet Med 1994;11:253-261.
20. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J: Fear of hypoglycemia: Quantification, validation, and utilization. Diabetes Care 1987;10:617-621.
21. BonsignoreM, BarkowK, Jessen F,Heun R:Validity of the fiveitem WHO Well-Being Index (WHO-5) in an elderly population. Eur Arch Psychiatry Clin Neurosci 2001;251:II27-II31.
22. Bradley C: Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Handbook of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers, 1994:111-132.
23. Awata S, Beck P, Yoshida S, Hirai M, Suzuki S, YamashitaM, Ohara A, Hinokio Y, Matsuoka H, Oka Y: Reliability and validity of the Japanese version of the WorldHealthOrganization- Five Well-Being Index in the context of detecting depression in diabetic patients. Psychiatry Clin Neurosci 2007;61:112-119. (Pubitemid 46089415)
24. de Wit M, Pouwer F, Gemke RJBJ, Delemarre-van de Waal H, Snoek FJ: Validation of the WHO-5 Well-Being Index in adolescents with type 1 diabetes. Diabetes Care 2007;30:2003-2006.
25. Löwe B, Spitzer RL, Gräfe K, Kroenke K, Quenter A, Zipfel S, Buchholz C, Witte S,HerzogW: Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses. J Affect Disord 2004;78:131-140.
26. Secnik Boye K, Matza L, Oglesby A, Malley K, Kim S, Hayes R, Brodows R: Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006;4:80.
27. Jacobson AM, de Groot M, Samson JA: The effects of psychiatric disorders and symptoms on quality of life in patients with type I and type II diabetes mellitus.Qual Life Res 1997;6:11-20.